Massachusetts Financial Services Co. MA Sells 33,887 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Massachusetts Financial Services Co. MA cut its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 419,490 shares of the company’s stock after selling 33,887 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.65% of Kymera Therapeutics worth $16,876,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares in the last quarter. KBC Group NV raised its stake in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Quarry LP bought a new stake in Kymera Therapeutics in the 3rd quarter valued at about $95,000. KLP Kapitalforvaltning AS bought a new stake in Kymera Therapeutics in the 4th quarter valued at about $310,000. Finally, Arizona State Retirement System increased its holdings in shares of Kymera Therapeutics by 15.5% during the fourth quarter. Arizona State Retirement System now owns 11,221 shares of the company’s stock worth $451,000 after purchasing an additional 1,503 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. BTIG Research assumed coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price on the stock. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 over the last quarter. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $22.07 on Monday. The firm’s fifty day moving average price is $34.02 and its two-hundred day moving average price is $40.99. The stock has a market cap of $1.43 billion, a PE ratio of -9.43 and a beta of 2.22. Kymera Therapeutics, Inc. has a fifty-two week low of $21.40 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.